在患者衍生细胞中使用非进化的dCas9表观基因组编辑器进行持久的HTT沉默
Jennifer J Waldo1,2,3,4,5,6, Julian A N M Halmai1,2,3,4,5,6, Ankita Singh1,2,3,4,5,6
1Ctr. for Interventional Genetics, University of California Davis Health, Sacramento, CA, USA.
Molecular therapy. Nucleic acids
|June 16, 2025
概括
这项研究表明,SpCas9表观遗传编辑在亨廷顿病模型中有效降低亨廷丁 (HTT) 基因的调节. 这种方法显示出作为这种神经退行性疾病的稳定,向治疗的前景.
科学领域:
- 神经遗传学 神经遗传学
- 基因治疗 基因治疗
- 表观遗传法规表观遗传法规表观遗传法规
背景情况:
- 亨廷顿病 (HD) 是一种神经退行性疾病,是由亨廷丁 (HTT) 基因中的三核酸重复扩张引起的.
- 使用核酶缺乏Cas9 (dCas9) 的表观遗传编辑通过降低引起HTT基因的调节,为HD提供了潜在的治疗策略.
研究的目的:
- 为了选dCas9变体与KRAB和DNMT3A/L融合,以检查它们降低HTT表达的能力.
- 评估dCas9变异在疾病相关细胞类型中的HTT基因沉默中最有效的dCas9变异的疗效和特异性.
主要方法:
- 选dCas9变体 (SpCas9,dxCas9,dCas9-VQR) 与表观遗传修饰剂 (KRAB,DNMT3A/L) 融合,以评估HTT下调.
- 减少表示双硫酸盐测序 (RRBS) 来分析目标和非目标DNA甲基化变化.
- 在快速分裂细胞系和患者衍生的神经干细胞中评估HTT沉默稳定性.
主要成果:
- 只有SpCas9显著降低了HTT表达的调节,而其他变体的效果不那么好.
- 基于SpCas9的系统诱导了高在点DNA甲基化,最小的离点效应.
- 在长达6周的时间里,HTT沉默在线粒学上稳定,并且在患者衍生的神经干细胞中有效.
结论:
- 基于SpCas9的表观遗传编辑是一种强大而特殊的策略,用于降低亨廷顿病中HTT基因的调节.
- 这种方法证明了亨廷顿病的治疗潜力,为基因沉默提供了一条新的途径.
相关概念视频
01:59CRISPR
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced Short...
01:28CRISPR/Cas9 Genome Editing
The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...